These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Partnership between academia and industry for drug discovery in Alzheimer's disease. Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952 [TBL] [Abstract][Full Text] [Related]
23. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? van Gool WA; Aisen PS; Eikelenboom P J Neurol; 2003 Jul; 250(7):788-92. PubMed ID: 12883918 [TBL] [Abstract][Full Text] [Related]
24. Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course. Schenk D Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S119-21. PubMed ID: 18631987 [TBL] [Abstract][Full Text] [Related]
25. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development. Foster NL; Andersen TC; Zamrini EY Alzheimers Dement; 2009 Mar; 5(2):159-62. PubMed ID: 19328451 [TBL] [Abstract][Full Text] [Related]
26. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Sabbagh JJ; Kinney JW; Cummings JL Neurobiol Aging; 2013 Jan; 34(1):169-83. PubMed ID: 22464953 [TBL] [Abstract][Full Text] [Related]
27. Biomarkers for the early stages of clinical development in Alzheimer's disease. Bordet R; Dartigues JF; Dubois B; Goehrs JM; Vernoux L; Semah F; Pasquier F; Bidaut-Mazel C; Therapie; 2010; 65(4):285-90, 277-283. PubMed ID: 20854749 [TBL] [Abstract][Full Text] [Related]
28. Priorities for research consortia on Alzheimer's disease. Gauthier S; Garcia A; Sano M; Robert P; Senanarong V; Woodward M; Brodaty H Alzheimers Dement; 2010 Jul; 6(4):359-62. PubMed ID: 20630416 [TBL] [Abstract][Full Text] [Related]
29. Methodological concerns: evaluating central nervous system (CNS) active compounds in Alzheimer's disease (AD). Cutler NR Prog Clin Biol Res; 1989; 317():1311-7. PubMed ID: 2602412 [No Abstract] [Full Text] [Related]
31. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. Shoaib M; Kamal MA; Rizvi SMD Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531 [TBL] [Abstract][Full Text] [Related]
32. Alzheimer's disease: clinical trials and drug development. Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346 [TBL] [Abstract][Full Text] [Related]
33. When will Alzheimer's disease be cured? A pharmaceutical perspective. Townsend M J Alzheimers Dis; 2011; 24 Suppl 2():43-52. PubMed ID: 21368375 [TBL] [Abstract][Full Text] [Related]
34. Diagnostic misconceptions? A closer look at clinical research on Alzheimer's disease. Kutschenko LK J Med Ethics; 2012 Jan; 38(1):57-9. PubMed ID: 21873309 [TBL] [Abstract][Full Text] [Related]
38. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Mani RB Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731 [TBL] [Abstract][Full Text] [Related]
39. Two recommendations for Alzheimer's medication protocols. Vann AS Clin Trials; 2013 Aug; 10(4):637-8. PubMed ID: 23900069 [No Abstract] [Full Text] [Related]
40. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics. Coley N; Gallini A; Andrieu S CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]